ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

ClinicalTrials.gov ID: NCT04211389

Public ClinicalTrials.gov record NCT04211389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis

Study identification

NCT ID
NCT04211389
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Enrollment
442 participants

Conditions and interventions

Interventions

  • ARQ-151 0.3% cream Drug
  • ARQ-151 vehicle cream Drug

Drug

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 16, 2019
Primary completion
Nov 22, 2020
Completion
Nov 22, 2020
Last update posted
Dec 6, 2022

2019 – 2020

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
29
Facility City State ZIP Site status
Arcutis Biotherapeutics Clinical Site 203 Scottsdale Arizona 85255
Arcutis Biotherapeutics Clinical Site 239 Beverly Hills California 90212
Arcutis Biotherapeutics Clinical Site 225 Encino California 91436
Arcutis Biotherapeutics Clinical Site 220 San Diego California 92123
Arcutis Biotherapeutics Clinical Site 208 Santa Monica California 90404
Arcutis Biotherapeutics Clinical Site 215 Santa Monica California 90503
Arcutis Biotherapeutics Clinical Site 223 Boynton Beach Florida 91436
Arcutis Biotherapeutics Clinical Site 237 DeLand Florida 32720
Arcutis Biotherapeutics Clinical Site 228 Largo Florida 33770
Arcutis Biotherapeutics Clinical Site 201 North Miami Beach Florida 33162
Arcutis Biotherapeutics Clinical Site 209 Sweetwater Florida 33172
Arcutis Biotherapeutics Clinical Site 214 Indianapolis Indiana 46250
Arcutis Biotherapeutics Clinical Site 217 Louisville Kentucky 40217
Arcutis Biotherapeutics Clinical Site 211 Lake Charles Louisiana 70605
Arcutis Biotherapeutics Clinical Site 213 Metairie Louisiana 70006
Arcutis Biotherapeutics Clinical Site 224 New Orleans Louisiana 70115
Arcutis Biotherapeutics Clinical Site 212 Detroit Michigan 48202
Arcutis Biotherapeutics Clinical Site 216 Fridley Minnesota 55432
Arcutis Biotherapeutics Clinical Site 227 Saint Joseph Missouri 64506
Arcutis Biotherapeutics Clinical Site 219 Las Vegas Nevada 89148
Arcutis Biotherapeutics Clinical Site 231 Las Vegas Nevada 89148
Arcutis Biotherapeutics Clinical Site 240 Reno Nevada 89703
Arcutis Biotherapeutics Clinical Site 236 Portsmouth New Hampshire 03801
Arcutis Biotherapeutics Clinical Site 222 Oklahoma City Oklahoma 73112
Arcutis Biotherapeutics Clinical Site 229 Broomall Pennsylvania 19008
Arcutis Biotherapeutics Clinical Site 233 Knoxville Tennessee 37922
Arcutis Biotherapeutics Clinical Site 221 Murfreesboro Tennessee 37130
Arcutis Biotherapeutics Clinical Site 206 Arlington Texas 76011
Arcutis Biotherapeutics Clinical Site 238 Houston Texas 77030
Arcutis Biotherapeutics Clinical Site 210 West Jordan Utah 84088
Arcutis Biotherapeutics Clinical Site 230 Richmond Virginia 23220

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04211389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 6, 2022 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04211389 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →